ClinicalTrials.gg

Program

zavegepant

Also written as “Zavegepant”, “Zavegepant (BHV-3500)” and “Zavegepant 10 mg IN”.

Its studies are mostly in Migraine Disorders · Asthma · COVID-19, led by Pfizer.

Furthest: phase 3, since Mar 6, 201913 company-led studies, 1 open or runningNext primary completion: Aug 12, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer131 open or runningphase 3since Mar 6, 2019Mar 6, 2019Aug 12, 2027phase 1 · NCT06995729

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 6, 2019First study: phase 3 study in Migraine DisordersFirst studyNCT03872453 · 2,154 enrolled · United States
  2. Apr 9, 2020Phase 3 study in COVID-19NCT04346615 · 47 enrolled · United States
  3. May 26, 2020Phase 3 study in Migraine DisordersNCT04408794 · 974 enrolled · United States
  4. Sep 11, 2020Phase 3 study in Migraine DisordersNCT04571060 · 1,978 enrolled · United States
  5. Mar 5, 2021Phase 3 study in Migraine DisordersNCT04804033 · 1,753 enrolled · United States
  6. Jul 26, 2021Phase 1 study in AsthmaNCT04987944 · 45 enrolled · Canada
  7. Jul 7, 20232 phase 1 studiesNCT05948085, NCT05960032
  8. Aug 3, 2023Phase 3 study in Migraine DisordersNCT05989048 · 1,414 enrolled · China, South Korea, Taiwan
  9. Oct 6, 2023Phase 3 study in Migraine DisordersNCT06103734
  10. Nov 14, 2023Phase 1 study in Biological AvailabilityNCT06137703 · 52 enrolled · United States
  11. May 28, 2024Phase 1 study in HealthyNCT06453356 · 12 enrolled · United States
  12. May 7, 2025Phase 1 study in Migraine DisordersNCT06995729 · 16 planned · United States

Ahead

  1. Aug 12, 2027Primary completion: phase 1 study in Migraine DisordersNCT06995729

TargetBeta

“A highly soluble small molecule calcitonin gene related peptide (CGRP) receptor antagonist, ”NCIt, by rule
“Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 antagonist; Calcitonin gene-related peptide type 1 receptor antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
atogepantruleAbbViephase 419
ubrogepantruleAbbViephase 413

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06995729Migraine Disorders · United States1RecruitingAug 12, 202716
NCT06453356Healthy · United States1CompletedSep 26, 202412
NCT06137703Biological Availability · United States1CompletedDec 7, 202252
NCT06103734Migraine Disorders3WithdrawnAug 2, 20270
NCT05989048Migraine Disorders · China, South Korea, Taiwan3CompletedMay 30, 20251,414
NCT05960032Healthy · China1CompletedDec 12, 202313
NCT05948085Migraine Disorders · United States1CompletedSep 5, 202314
NCT04987944Asthma · Canada1TerminatedMar 29, 202345
NCT04804033Migraine Disorders · United States3TerminatedMar 21, 20241,753
NCT04571060Migraine Disorders · United States3CompletedOct 10, 20211,978
NCT04408794Migraine Disorders · United States3CompletedDec 9, 2021974
NCT04346615COVID-19 · United States3TerminatedApr 29, 202247
NCT03872453Migraine Disorders · United States3CompletedOct 31, 20192,154

How it is read

Names in the registry

  • “Zavegepant”, 6 entries
  • “Zavegepant (BHV-3500)”, 2 entries
  • “Zavegepant 10 mg IN”, 1 entry
  • “Zavegepant 10 mg”, 1 entry
  • “BHV-3500 (zavegepant)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.